<span>BCL⁃2抑制剂维奈托克在较高危组骨髓增生异常综合征中的治疗进展</span>

刘艺裴仁治

Advances of BCL ⁃ 2 inhibitor Venetoclaxfor higher ⁃ risk groups of myelodysplastic syndromes

LIU Yi, PEI Renzhi.

实用医学杂志 . 2022, (16): 2106 -2109 . DOI: 10.3969/j.issn.1006⁃5725.2022.16.023